PMID- 28427156
OWN - NLM
STAT- MEDLINE
DCOM- 20180403
LR  - 20220409
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 17
DP  - 2017 Apr 25
TI  - The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential 
      mechanism of chemoimmunotherapy resistance in BL.
PG  - 27839-27853
LID - 10.18632/oncotarget.15711 [doi]
AB  - Following a multivariant analysis we demonstrated that children and adolescents 
      with Burkitt lymphoma (BL) and a 13q14.3 deletion have a significant decrease in 
      event free survival (EFS) despite identical short intensive multi-agent 
      chemotherapy. However, how this deletion in the 13q14.3 region is associated with 
      a significant decrease in EFS in children and adolescents with BL is largely 
      unknown. The gene Deleted in Lymphocytic Leukemia 1 (DLEU1) is located in the 
      region of 13q14.3. Here, we report that DLEU1 expression is implicated in the 
      regulation of BL programmed cell death, cell proliferation, and expression of 
      apoptotic genes in transcription activator-like effector nuclease 
      (TALEN)s-induced DLEU1 knockdown and DLEU1 overexpressing BL cell lines. 
      Furthermore, NSG mice xenografted with DLEU1 knockdown BL cells had significantly 
      shortened survival (p < 0.05 and p < 0.005), whereas those xenografted with DLEU1 
      overexpressing BL cells had significantly improved survival (p < 0.05 and p < 
      0.0001), following treatment with rituximab and/or cyclophosphamide. These data 
      suggest that DLEU1 may in part function as a tumor suppressor gene and confer 
      chemoimmunotherapy resistance in children and adolescents with BL.
FAU - Lee, Sanghoon
AU  - Lee S
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
AD  - Departments of Cell Biology and Anatomy, New York Medical College, Valhalla, New 
      York, USA.
FAU - Luo, Wen
AU  - Luo W
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
FAU - Shah, Tishi
AU  - Shah T
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
FAU - Yin, Changhong
AU  - Yin C
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
FAU - O'Connell, Timmy
AU  - O'Connell T
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
AD  - Departments of Microbiology and Immunology, New York Medical College, Valhalla, 
      New York, USA.
FAU - Chung, Tae-Hoon
AU  - Chung TH
AD  - Cancer Science Institute of Singapore, National University of Singapore, 
      Singapore.
FAU - Perkins, Sherrie L
AU  - Perkins SL
AD  - Department of Pathology and ARUP Laboratories, University of Utah, Salt Lake 
      City, Utah, USA.
FAU - Miles, Rodney R
AU  - Miles RR
AD  - Department of Pathology and ARUP Laboratories, University of Utah, Salt Lake 
      City, Utah, USA.
FAU - Ayello, Janet
AU  - Ayello J
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
FAU - Morris, Erin
AU  - Morris E
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
FAU - Harrison, Lauren
AU  - Harrison L
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
FAU - van de Ven, Carmella
AU  - van de Ven C
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
FAU - Cairo, Mitchell S
AU  - Cairo MS
AD  - Departments of Pediatrics, New York Medical College, Valhalla, New York, USA.
AD  - Departments of Cell Biology and Anatomy, New York Medical College, Valhalla, New 
      York, USA.
AD  - Departments of Microbiology and Immunology, New York Medical College, Valhalla, 
      New York, USA.
AD  - Departments of Pathology, New York Medical College, Valhalla, New York, USA.
AD  - Departments of Medicine, New York Medical College, Valhalla, New York, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (DLEU1 lncRNA, human)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - EC 3.1.- (Transcription Activator-Like Effector Nucleases)
SB  - IM
MH  - Adolescent
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Antineoplastic Agents, Immunological/pharmacology/therapeutic use
MH  - Apoptosis
MH  - Burkitt Lymphoma/*drug therapy/*genetics/mortality/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Child
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 13/*genetics
MH  - Cyclophosphamide/pharmacology/therapeutic use
MH  - Disease-Free Survival
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Gene Knockdown Techniques
MH  - Genes, Tumor Suppressor
MH  - HEK293 Cells
MH  - Humans
MH  - Mice
MH  - Mice, Inbred NOD
MH  - RNA, Long Noncoding
MH  - Rituximab/pharmacology/therapeutic use
MH  - Signal Transduction
MH  - Transcription Activator-Like Effector Nucleases/genetics
MH  - Tumor Suppressor Proteins/genetics/*metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5438612
OTO - NOTNLM
OT  - B-NHL
OT  - DLEU1
OT  - chemoimmunotherapy
OT  - genome editing
OT  - tumor suppressor
COIS- CONFLICTS OF INTEREST All authors declare no financial conflicts of interest.
EDAT- 2017/04/22 06:00
MHDA- 2018/04/04 06:00
PMCR- 2017/04/25
CRDT- 2017/04/22 06:00
PHST- 2016/11/17 00:00 [received]
PHST- 2017/02/12 00:00 [accepted]
PHST- 2017/04/22 06:00 [pubmed]
PHST- 2018/04/04 06:00 [medline]
PHST- 2017/04/22 06:00 [entrez]
PHST- 2017/04/25 00:00 [pmc-release]
AID - 15711 [pii]
AID - 10.18632/oncotarget.15711 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Apr 25;8(17):27839-27853. doi: 10.18632/oncotarget.15711.